What Kaffetin Treats: Main Uses and Benefits

The formulation is commonly used in contexts where symptoms of pain require additional support. Opioid-containing pain relievers are relevant for acute moderate pain that cannot be relieved by other standard non-opioid options. This potentiated support is considered relevant for easing symptoms related to headache, toothache (dental pain), neuralgia, periodic pain, and musculoskeletal pain (rheumatic discomfort).

The medication is applied in addressing symptom clusters that may interfere with daily functioning, commonly used when short-term symptomatic assistance is needed. This use supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability during periods of heightened discomfort. This application helps ease challenging, often recurrent, symptoms, and is relevant for managing the symptom burden where pain is accompanied by fever, supporting multiple symptom-focused domains.

---

Quick Fact: Support for Acute Discomfort

Property	Description
Primary Use Focus	Symptomatic management of acute moderate pain
Key Therapeutic Benefit	Robust pain support; assists with maintaining functional stability
Relevance	Applied in contexts where additional symptomatic support is needed
Symptom Scope	Pain, often accompanied by tension or systemic imbalance

Regulatory References

1. European Medicines Agency guidance on Codeine-containing medicines

Population Eligibility: Contraindications and Restrictions

The official regulatory profile for Каффетин, a combination analgesic, defines eligibility through specific exclusions and conditional use requirements, primarily due to the Codeine component.

Absolute Contraindications (Must Not Use)

Use is strictly prohibited for children under 12 years of age and for all breastfeeding mothers and pregnant women. It is also contraindicated for patients known to be CYP2D6 ultra-rapid metabolizers, due to the risk of toxicity from Codeine's active metabolite. Further prohibitions include individuals with severe hepatic impairment, severe renal failure, G6PD deficiency, acute intermittent porphyria, or conditions involving bone marrow suppression.

Restricted and Conditional Use

Adolescents aged 12 to 18 years have a restricted eligibility status; use is only permitted to treat acute moderate pain that cannot be relieved by non-opioid painkillers (such as paracetamol or ibuprofen). The medicine is not recommended for adolescents with compromised respiratory function. Caution is also required for older adults and patients with moderate renal or hepatic impairment.

Interactions with other medicines and products

The interaction profile of this multi-component drug is defined by restrictions and pharmacokinetic changes documented by regulatory authorities, primarily concerning the Codeine and Acetaminophen components.

Official Interaction Restrictions

Classification	Interacting Substance / Category	Restriction / Outcome Type
Contraindicated	Other Acetaminophen-Containing Products	Strictly prohibited co-use to mitigate the risk of severe dose-dependent liver toxicity.
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Prohibited due to the risk of severe CNS excitation or serotonergic effects.
High Risk	Alcohol and CNS Depressants	Co-administration is documented to cause additive CNS depression, increasing the risk of profound sedation and respiratory depression.

Pharmacokinetic and Metabolic Interactions

The Codeine component is subject to metabolic pathway alterations. Co-administration with CYP2D6 Inhibitors (e.g., fluoxetine, quinidine) is officially documented to reduce the formation of Codeine’s active metabolite, which may result in a loss of expected analgesic efficacy. Conversely, the Acetaminophen component increases the potential for hepatotoxicity when co-administered with certain hepatic enzyme inducers. Warfarin (an oral anticoagulant) may experience an increased effect when co-used with Acetaminophen, particularly at higher doses, necessitating clinical monitoring as stated in regulatory materials. A mandatory 14-day clearance period is required after discontinuing MAOIs before administering Codeine-containing medication to reduce the potential for interaction risk.

Mechanism of Action

This medication utilizes a multi-component mechanism that acts across peripheral tissues and the Central Nervous System (CNS).

One active ingredient functions as a non-selective inhibitor of Cyclooxygenase (COX) enzymes. This interaction limits the downstream production of prostaglandins, chemical mediators that influence peripheral nerve ending sensitization and modulate signals affecting the body's thermostatic set point.

Simultaneously, two components engage CNS receptors. One acts as a weak agonist at opioid receptors, reducing the release of specific neurotransmitters to decrease the transmission and perception of incoming neural signals. The other component is an antagonist at adenosine receptors, which results in increased neuronal activity.

Crucially, a fourth component acts to accelerate the rate at which all active ingredients are absorbed into the bloodstream, ensuring their rapid systemic availability and allowing for a synchronous engagement of the combined physiological mechanisms.

Administration Guidelines: Каффетин (Caffetin)

These guidelines detail the use of Каффетин, addressing route, dosage, and frequency. The information pertains to multi-component formulations containing Paracetamol, Propyphenazone, Caffeine, and Codeine.

Route of Administration and Intake

Каффетин is formulated as a tablet for oral administration (swallowing). It is essential to take the tablet with a sufficient amount of water. For some formulations, administration is recommended 1–2 hours after a meal.

Population	Standard Single Dose	Maximum Daily Dose	Frequency
Adults and Age 16 Years	1 to 2 tablets	6 tablets	Repeat up to 3 times a day
Adolescents 12-16 Years	1/2 to 1 tablet	6 tablets	Repeat up to 3 times a day

Important Administration Limits

The dosage must not exceed the maximum daily dose of 6 tablets. The use of Каффетин is intended for short-term treatment. The course duration is typically limited, not exceeding 3 to 5 consecutive days, depending on the specific use context.

Special Conditions

For patients with severe renal impairment (creatinine clearance <10 ml/min), the interval between two doses of the Paracetamol-containing product must be extended to at least 8 hours. Children under 12 years are generally not recommended to use the product.

Research evidence / Overview of studies for Каффетин

Evidence for Acute Moderate Pain Management

This section summarizes the structure of the regulatory and peer-reviewed evidence—primarily Randomized Controlled Trials (RCTs) and Systematic Reviews—that examined the combination's application in research exploring symptom patterns related to acute pain, such as post-operative and dental pain.

High-quality research, including Systematic Reviews and short-term RCTs, was applied in studies examining patient-reported experiences for outcomes related to physical discomfort. Researchers examined outcomes related to physical discomfort, including the total reported change in symptom intensity over a specific time, and the percentage of participants achieving a defined level of reported discomfort change.

Data show patterns related to a greater proportion of participants achieving a defined level of reported discomfort change compared to those who received a placebo or the non-opioid component alone. Studies report how symptoms evolved in the observed populations over short observation periods, typically only 4 to 6 hours. This evidence contributes to understanding symptom patterns in conditions characterized by acute or disruptive episodes.

Studies on the Role of Caffeine as an Analgesic Adjuvant

This area outlines the specific research structure that investigated the role of the CNS stimulant component (Caffeine) in observed changes to patient-reported outcomes describing perceived discomfort, focusing on studies that compared combination formulas with and without the adjuvant.

Trials frequently describe patterns observed in the studies where the inclusion of caffeine was associated with an increased proportion of patients achieving a defined level of reported discomfort change. Findings indicate that the addition of caffeine may be associated with measurements describing changes related to how quickly participants reported a change in symptom intensity. This research highlights changes measured during the study period, helping to contextualize how patients reported their experience with the combination.

Long-Term Evidence and Duration of Follow-up

The follow-up durations were limited across the high-quality evidence base. Consequently, there is limited information for long-term outcomes or the consequences of repeated use beyond the immediate, acute administration studied in trials. Long-term outcomes or functional outcomes related to sustained use are not fully established by the existing research.

Key Studies & References

1. Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain: a meta-analysis (NCBI Bookshelf)
2. A randomized, controlled trial of acetaminophen, ibuprofen, and codeine for acute pain relief in children with musculoskeletal trauma

Common questions about Каффетин (FAQ)

Q: What types of pain is Каффетин officially indicated to treat?

Regulatory documents state that this medicine is indicated for the symptomatic management of mild to moderate pain. This includes common types of pain such as headache, migraine, toothache, joint and muscle pain, and menstrual discomfort. Additionally, one of the active components provides an antipyretic (fever-reducing) effect.

Q: How quickly does the effect of Каффетин typically begin, based on official studies?

Studies and official information regarding this combination suggest a rapid onset of action. The analgesic effects are typically observed in research participants within the first 30 to 60 minutes after taking the medicine.

Q: What is the expected duration of pain relief from one dose of Каффетин?

Based on the research evidence available for this combination, the duration of significant pain relief is measured in short observation periods. Studies reported outcomes based on pain relief scores achieved up to approximately four hours following administration of a single dose.

Q: Is there a risk of stomach irritation mentioned for Каффетин?

The product contains the component Propyphenazone, which is associated with a potential for gastrointestinal disturbances. Regulatory documents list severe conditions like gastrointestinal ulcers or bleeding as specific reasons why the medicine should not be used.

Q: Can Каффетин be taken alongside certain common cold and flu medications?

Official product information strictly prohibits using this medicine alongside any other product that contains Acetaminophen (Paracetamol). This is a critical warning to mitigate the risk of severe liver toxicity. Acetaminophen is a very common ingredient found in many cold and flu preparations.

Q: Why is Каффетин often used for headache and migraine pain specifically?

Official regulatory information confirms that headache and migraine are both listed as therapeutic indications for the use of this medicine.

Q: Does Каффетин contain aspirin or other ingredients that might affect blood clotting?

The formulation does not contain Aspirin. However, one of the components, Propyphenazone, is documented to interact with certain blood thinning medicines, known as anticoagulants. These interactions have been associated with an increased risk of bleeding or hemorrhage.

Q: What are the restrictions on using Каффетин for individuals with asthma or other respiratory issues?

Official product information lists the presence or a history of conditions like bronchial asthma as a specific contraindication for using the product. Furthermore, the medicine is restricted for use in adolescents who have compromised respiratory function due to the Codeine component.

Q: Does official information address what happens in the event of an overdose of Каффетин?

Regulatory documents explicitly carry a severe warning that an overdose, especially due to the Paracetamol content, can lead to severe liver failure and death. In the event more than the recommended amount is taken, regulatory guidance describes that immediate medical assistance should be sought, even if no immediate symptoms are present.

Q: Is it normal to feel slightly jittery after taking Каффетин due to the caffeine content?

Official product information confirms that the caffeine component can cause nervous system effects. These are described in regulatory documents using terms such as tremors, restlessness, and anxiety, which align with the common description of feeling "jittery."

Q: Is Каффетин a prescription-only medicine or an over-the-counter (OTC) product in most countries?

The regulatory status of this drug varies by region, but it is regulated as an Over-The-Counter (OTC) medicine in several countries where it is available.

Q: Is there any official mention of the risk of developing a medication-overuse headache (MOH) with Каффетин?

While the term Medication-Overuse Headache (MOH) may not be explicit, some official warnings for opioid-containing combinations address the potential for 'rebound' headaches. These are described as new or worsening headaches that may occur as a withdrawal symptom when the medicine is stopped suddenly after repeated use.

Q: Does the official documentation describe Каффетин as having a potential for dependence or misuse?

Due to the presence of the opioid component Codeine, official documents state that the medicine carries a risk for abuse and addiction. This potential risk is stated to exist even when the medicine is used at the recommended dosage.

Q: Where can patients find the full Summary of Product Characteristics (SmPC) for Каффетин?

Patients typically receive the Patient Information Leaflet (PIL) with the product. The full Summary of Product Characteristics (SmPC) is a technical document that can often be found in the public sections of national regulatory agency websites or drug registries in the country where the medicine is marketed.

Q: Are there differences in the available strengths of Каффетин across different countries?

Regulatory data indicates that the composition and strength of the product can vary depending on the country of sale. Different formulations are marketed under the Каффетин brand name, such as products containing or lacking Codeine, or specialized products for specific symptoms like cold and flu.

Q: What is the process for reporting a side effect experienced with Каффетин to regulatory bodies?

The official process for reporting side effects is known as pharmacovigilance and is overseen by government health agencies. Official guidance indicates that patients utilize the official reporting system of the national regulatory authority in the country where the medicine was obtained, such as a "Yellow Card" or "MedWatch" program.

Q: What are the official recommendations if a person misses a dose of Каффетин?

The general principle found in official drug guidelines cautions against compensating for a missed dose by taking a double amount, as this increases the risk of side effects. Official information states that patients should refer to and follow the specific instructions provided on the product’s Patient Information Leaflet.

Q: Are there official warnings about taking Каффетин before operating machinery or driving?

Official product information advises caution during treatment regarding the operation of motor vehicles and machinery. This warning applies to engaging in any activity that requires increased concentration and psychomotor speed due to the known central nervous system effects of the active components.

Q: What is the legal classification of Каффетин in major markets like the EU or the US?

The medicine is regulated as an Over-The-Counter (OTC) drug in several European markets. However, the specific formulation containing Propyphenazone and Codeine is not currently approved for marketing by the US Food and Drug Administration (FDA).

Q: Are there different versions of Каффетин (e.g., Каффетин cold, Каффетин forte)?

Regulatory documentation confirms that other specialized versions are marketed under the Каффетин brand name. These include products specifically formulated for symptoms like cold and flu, or those for menstrual discomfort.

Storage Requirements

Official regulatory documentation requires that Каффетин tablets be stored at a temperature not above 25 C to maintain product stability. The medicine must be stored in the original package to ensure protection from light and moisture. Tablets should not be refrigerated or frozen. Due to the presence of Codeine, all tablets must be stored securely out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Каффетин must be handled as pharmaceutical waste and disposed of according to local requirements. The official guidance strongly recommends using authorized drug take-back locations or official mail-back programs for opioid-containing medicines. Medicines should not be disposed of via wastewater (flushed down drains) or placed in general household trash.